Venus Remedies Ltd (VENUSREM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 526953 | NSE: VENUSREM | Pharmaceuticals & Drugs | Small Cap

Venus Remedies Share Price

724 -28.90 -3.84%
as on 05-Dec'25 12:17

Venus Remedies Ltd (VENUSREM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 526953 | NSE: VENUSREM | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Venus Remedies

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Venus Remedies stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
14.31
Market Cap:
1,006.4 Cr.
52-wk low:
272.2
52-wk high:
808.5

Is Venus Remedies Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Venus Remedies: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Venus Remedies Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 5.4%2%1.2%-0.7%0.9%12.4%7.9%7.7%8.7%13.2%-
Value Creation
Index
-0.6-0.9-0.9-1.1-0.9-0.1-0.4-0.5-0.4-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 418400372322339548600556601648696
Sales YoY Gr.--4.4%-6.9%-13.6%5.4%61.5%9.5%-7.4%8.3%7.7%-
Adj EPS 1.5-15-24.9-20.1-4.633.127.11618.226.152.6
YoY Gr.--1121.8%NANANANA-18%-40.8%13.5%43.4%-
BVPS (₹) 382.5314.9293.2269.4262313.2329.5344.4364.7419.7444.6
Adj Net
Profit
1.7-18.5-30.8-24.8-5.740.836.221.424.334.970
Cash Flow from Ops. 46.958.931.245.377.613241.136.637.386.4-
Debt/CF from Ops. 7.25.39.86.62.80.411.21.10-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5%13.8%2.6%7.7%
Adj EPS 37.7%NA-1.3%43.4%
BVPS1%9.9%8.4%15.1%
Share Price 18.5% 40% 54.8% 124%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
0.4-4.5-8.2-7.1-1.711.38.64.85.16.712.2
Op. Profit
Mgn %
19.412.710.610.1129.810.410.89.99.812.7
Net Profit
Mgn %
0.4-4.6-8.3-7.7-1.77.563.945.410.1
Debt to
Equity
0.80.80.90.90.70.10.10.10.100
Working Cap
Days
270270285337338188152180177168109
Cash Conv.
Cycle
153152153170147705683877276

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Venus Remedies Ltd.

Standalone Consolidated
TTM EPS (₹) 52.2 52.6
TTM Sales (₹ Cr.) 691 696
BVPS (₹.) 467.3 444.6
Reserves (₹ Cr.) 611 581
P/BV 1.61 1.69
PE 14.42 14.31
From the Market
52 Week Low / High (₹) 272.20 / 808.50
All Time Low / High (₹) 1.00 / 761.65
Market Cap (₹ Cr.) 1,006
Equity (₹ Cr.) 13.4
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Venus Remedies:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Venus Remedies - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Venus Remedies

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales418400372322339548600556601648
Operating Expenses 337349333289299494538495542584
Manufacturing Costs20474026262736383543
Material Costs239227205182174341387331355379
Employee Cost 32343942464652576775
Other Costs 46414839538062708588
Operating Profit 81513933415462606064
Operating Profit Margin (%) 19.4%12.7%10.6%10.1%12.0%9.8%10.3%10.8%9.9%9.8%
Other Income 24265208101221
Interest 3836362513130000
Depreciation 42403434323534322623
Exceptional Items 000-9-92300010
Profit Before Tax 4-22-28-30-84936384572
Tax 2-53-12-13-4111627
Profit After Tax 2-17-31-29-106241272845
PAT Margin (%) 0.4%-4.3%-8.2%-8.9%-2.9%11.3%6.8%4.8%4.7%7.0%
Adjusted EPS (₹)1.5-13.8-24.9-23.2-8.150.030.519.921.333.9
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 438389362333323387440460488561
Share Capital 11121212121213131313
Reserves 426376350320311374427447474548
Minority Interest0000000000
Debt314281259229158514342412
Long Term Debt19116213711672473939390
Short Term Debt1231191211138644432
Trade Payables25302936377150515392
Others Liabilities 66661011351264746484561
Total Liabilities 843765751733644556579601627716

Fixed Assets

Gross Block680687703707624616613604618637
Accumulated Depreciation227280314343335355372388399407
Net Fixed Assets 452406389364289262241216219229
CWIP 80666565252525262126
Investments 0000000201984
Inventories143141138143141120126120122100
Trade Receivables624747383132397780112
Cash Equivalents 744323150546880
Others Assets 981011071201568698889883
Total Assets 843765751733644556579601627716

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 475931457813241373786
PBT 4-22-28-2112536384562
Adjustment 56716661422226232015
Changes in Working Capital -1310-852161-22-25-1225
Tax Paid 00000000-15-15
Cash Flow From Investing Activity 3-18-11-11-556-17-51-7-76
Capex -0-230-10-858-13-8-13-18
Net Investments 00000-2-5-451-63
Others 34-11-1311255
Cash Flow From Financing Activity -46-44-39-35-73-162-9-1-1-1
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -11-12-9-5-34-88-9-0-1-1
Interest Paid -35-33-32-22-12-7-0-0-0-0
Dividend Paid 0000000000
Others -012-8-28-68-000-0
Net Cash Flow 3-4-20-1-02615-15299

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)0.38-4.13-8.18-8.23-3.0517.49.855.96.018.64
ROCE (%)5.3521.17-0.670.912.377.897.728.6713.17
Asset Turnover Ratio0.50.50.490.430.490.911.060.940.980.97
PAT to CFO Conversion(x)23.5N/AN/AN/AN/A2.1311.371.321.91
Working Capital Days
Receivable Days54504648372121384854
Inventory Days1251301371591538775817363
Payable Days42445366765857565470

Venus Remedies Ltd Stock News

Venus Remedies Ltd FAQs

The current trading price of Venus Remedies on 05-Dec-2025 12:17 is ₹724.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Venus Remedies stood at ₹1,006.4.
The latest P/E ratio of Venus Remedies as of 04-Dec-2025 is 14.42.
The latest P/B ratio of Venus Remedies as of 04-Dec-2025 is 1.61.
The 52-week high of Venus Remedies is ₹808.5 and the 52-week low is ₹272.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Venus Remedies is ₹691.1 ( Cr.) .

About Venus Remedies Ltd

Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.

Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.

Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.

Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.

Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.

Products

The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.

Milestone/ Awards

2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNIL” in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×